Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry Completed upsized initial public offering, including full exercise of the underwriters' purchase option, and a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds Cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds raised from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029 ALAMEDA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate and pipeline updates.